Targeted attack on rare lung cancer mutations
NCT ID NCT04504071
Summary
This study is testing a drug called dacomitinib for people with advanced non-small cell lung cancer who have specific, less common genetic mutations in their tumors. It aims to see how well the drug controls the cancer and how safe it is. About 30 participants will take the oral drug daily until their cancer worsens or they can no longer benefit from it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest hospital
Shanghai, Shanghai Municipality, 200030, China
Conditions
Explore the condition pages connected to this study.